Quick Answer
Revolution Medicines, Inc. reported Research And Development Expense of $987.33 million for the year ending 2025.
- Revolution Medicines, Inc. showed an increase of +66.7% in Research And Development Expense from 2024 to 2025.
- This data is from Revolution Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $21.19 million | Q2 2019: $20.12 million | Q3 2019: $22.96 million | Q1 2020: $27.46 million | Q2 2020: $32.92 million | Q3 2020: $34.87 million | Q1 2021: $40.86 million | Q2 2021: $45.94 million | Q3 2021: $46.47 million | Q1 2022: $56.49 million | Q2 2022: $61.00 million | Q3 2022: $69.46 million | Q1 2023: $68.95 million | Q2 2023: $97.98 million | Q3 2023: $107.74 million | Q1 2024: $118.02 million | Q2 2024: $134.93 million | Q3 2024: $151.75 million | Q1 2025: $205.75 million | Q2 2025: $224.13 million | Q3 2025: $262.51 million.
- Over the full 8 years of available data (2018 to 2025), Revolution Medicines, Inc.'s Research And Development Expense has grown by 1,832.8%.
- Historical annual values: Fiscal year 2025: $987.33 million | Fiscal year 2024: $592.23 million | Fiscal year 2023: $423.14 million | Fiscal year 2022: $253.07 million | Fiscal year 2021: $186.95 million | Fiscal year 2020: $132.25 million | Fiscal year 2019: $91.76 million | Fiscal year 2018: $51.08 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: